Sugi Predict

Sugi Predict / Targets / FSHR

FSHR

Follicle-stimulating hormone receptor · P23945 · FSHR on Sugi Atlas →

3,532 patent compounds predicted against FSHR, 2,103 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6140288 SCHEMBL6140288 1.00 20/20
SCHEMBL6140399 SCHEMBL6140399 1.00 20/20
SCHEMBL6140613 SCHEMBL6140613 1.00 20/20
SCHEMBL6140715 SCHEMBL6140715 1.00 20/20
SCHEMBL6140785 SCHEMBL6140785 1.00 20/20
SCHEMBL6140944 SCHEMBL6140944 1.00 20/20
SCHEMBL6141030 SCHEMBL6141030 1.00 20/20
SCHEMBL6141095 SCHEMBL6141095 1.00 20/20
SCHEMBL6141134 SCHEMBL6141134 1.00 20/20
Dimethylamine Dimethylamine (SCHEMBL6140798) 0.94 20/20
SCHEMBL2190386 SCHEMBL2190386 0.85 20/20
SCHEMBL6140403 SCHEMBL6140403 0.85 20/20
SCHEMBL6140632 SCHEMBL6140632 0.84 20/20
SCHEMBL3394213 SCHEMBL3394213 0.81 20/20
SCHEMBL6140784 SCHEMBL6140784 0.81 20/20
SCHEMBL6140268 SCHEMBL6140268 0.79 20/20
SCHEMBL6140294 SCHEMBL6140294 0.79 20/20
SCHEMBL6140651 SCHEMBL6140651 0.79 20/20
SCHEMBL6141131 SCHEMBL6141131 0.79 20/20
SCHEMBL6140748 SCHEMBL6140748 0.78 20/20

Clinical trials — most relevant to FSHR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Vitamin D for Polycystic Ovary Syndrome Clomiphene Resistant Women PHASE4COMPLETED
The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation PHASE4UNKNOWN
Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial PHASE4COMPLETED
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women PHASE3COMPLETED
Triggering of Follicular Maturation PHASE3COMPLETED
Initiation of Ovarian Stimulation With Recombinant-human FSH (Bemfola®) in the Late Follicular Phase PHASE3COMPLETED
Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS) PHASE3UNKNOWN
Follicle Stimulating Hormone (FSH) Glycosylation in Women: Effect of Estradiol PHASE2UNKNOWN
TRial on the Endocrine Activity of Neoadjuvant Degarelix PHASE2COMPLETED
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids. PHASE2COMPLETED
Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program EARLY_PHASE1COMPLETED
Follicle-Stimulating Hormone (FSH) and the Onset of Puberty EARLY_PHASE1COMPLETED
A Post Marketing Assessment of Gonal f Solution for Injection in a Prefilled Pen for Follicular Stimulation in in Vitro Fertilisation/Embryo Transfer (IVF-ET) Cycles nanCOMPLETED
C Terminal Variants of FSH Receptor nanCOMPLETED
A Proof of Concept Study of Serum Progesterone Levels for IVF/ICSI Following HCG Trigger for Oocyte Maturation nanCOMPLETED
Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes and Suboptimal Response nanCOMPLETED
Combination Letrozole and Clomiphene Citrate Versus Letrozole Alone nanUNKNOWN
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression nanCOMPLETED
Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle nanCOMPLETED
Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone nanUNKNOWN
Serum FSH Levels During Controlled Ovarian Stimulation nanNOT_YET_RECRUITING
Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients nanCOMPLETED
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients nanUNKNOWN
N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS nanUNKNOWN
Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles nanUNKNOWN
A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation nanCOMPLETED
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation nanRECRUITING
Follicle Stimulating Hormone (FSH) Receptor Polymorphisms in In-Vitro Fertilization Cycles. nanCOMPLETED
Hormone Evaluation in Artificial Reproductive Technology nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FSHR binder may also engage these)

ProteinNameSimilarity
P20395 — 1.000 P20395 →
P47799 — 1.000 P47799 →
Q6R6L8 — 1.000 Q6R6L8 →
P49059 — 1.000 P49059 →
P32212 — 1.000 P32212 →
P35378 — 1.000 P35378 →
Q6YNB6 — 1.000 Q6YNB6 →
P35376 — 1.000 P35376 →
Q95179 — 1.000 Q95179 →
Q5GJ04 — 1.000 Q5GJ04 →
Q8R428 — 1.000 Q8R428 →
P35379 — 1.000 P35379 →
P79763 — 0.999 P79763 →
Q7ZTV5 — 0.995 Q7ZTV5 →
P16582 — 0.993 P16582 →
O02721 — 0.988 O02721 →
Q28585 — 0.987 Q28585 →
Q28005 — 0.987 Q28005 →
P30730 — 0.986 P30730 →
Q27987 — 0.985 Q27987 →
TSHR Thyrotropin receptor 0.985 landscape →
P21463 — 0.984 P21463 →
LHCGR Lutropin-choriogonadotropic hormone receptor 0.984 landscape →
Q9BGN4 — 0.983 Q9BGN4 →
P14763 — 0.981 P14763 →
P47750 — 0.981 P47750 →
Q8SPP9 — 0.980 Q8SPP9 →
P16235 — 0.979 P16235 →
P56495 — 0.977 P56495 →
Q90674 — 0.977 Q90674 →